EOG Resources Inc vs Heron Therapeutics Inc — how do they compare? EOG Resources Inc trades at $144 (market cap $74.60B), while Heron Therapeutics Inc trades at $0.33 (market cap $63.41M). The key difference: EOG Resources Inc is far larger — about 1176.5× Heron Therapeutics Inc's market cap, and EOG Resources Inc pays a 2.87% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| EOG | HRTX | |
|---|---|---|
Market Cap | $74.60B | $63.41M |
Sector | Energy | Health |
52-Week High | $149.89 | $1.49 |
52-Week Low | $101.78 | $0.32 |
Enterprise Value | $77.94B | $161.31M |
Dividend Yield | 2.87% | — |
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $134.74, down 1.07% with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $5.07, beating estimates, with revenue growth driven by higher oil prices and production. Valuation metrics remain attractive with P/E of 10.49 and EV/EBITDA of 5.32, while maintaining robust profitability with 25.81% net margin and 22.51% ROE.
EOG presents a compelling value opportunity with strong earnings momentum and shareholder returns through dividends. However, negative cash flow trends and energy price volatility pose near-term risks. Analyst consensus remains bullish with $162.11 price target, representing 20% upside potential from current levels.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Trailing returns across standard periods
Latest headlines on both assets
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →